ABUS Arbutus Biopharma Corporation

2.39
0  0%
Previous Close 2.39
Open 2.38
Price To Book -2.69
Market Cap 135,871,911
Shares 56,850,172
Volume 7,364
Short Ratio
Av. Daily Volume 724,983
Stock charts supplied by TradingView

NewsSee all news

  1. Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    WARMINSTER, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today reports its third quarter 2019 financial results and

  2. Arbutus to Report Third Quarter 2019 Financial Results

    WARMINSTER, Pa., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its third quarter financial

  3. Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B

    WARMINSTER, Pa., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced its decision to discontinue the clinical

  4. Arbutus to Participate in Upcoming Investor Conferences

    WARMINSTER, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company will be

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial ongoing but no plans to continue further development.
ARB-1467, tenofovir, and pegylated interferon
Hepatitis B (HBV)
Decision regarding clinical development due early 2020.
AB-452
Hepatitis B
Development to be discontinued - noted October 3, 2019.
AB-506
Hepatitis B (HBV)
Phase 1a/b data due 1Q 2020.
AB-729
Hepatitis B (HBV)

Latest News

  1. Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    WARMINSTER, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today reports its third quarter 2019 financial results and

  2. Arbutus to Report Third Quarter 2019 Financial Results

    WARMINSTER, Pa., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its third quarter financial

  3. Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B

    WARMINSTER, Pa., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced its decision to discontinue the clinical

  4. Arbutus to Participate in Upcoming Investor Conferences

    WARMINSTER, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company will be